Results 71 to 80 of about 16,388 (147)

Practical recommendations for treating patients with chronic kidney disease in Australia: a multidisciplinary approach

Internal Medicine Journal, Volume 56, Issue 6, Page 966-975, June 2026.
Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich, W. P. Abhayaratna, R. Audehm, E. I. Ekinci, R. J. MacIsaac, A. J. Nelson, A. Sharma, C. Pollock   +7 more
wiley   +1 more source

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

Journal of Lipid Research, 2007
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism.
Mark J. Graham, Kristina M. Lemonidis, Charles P. Whipple, Amuthakannan Subramaniam, Brett P. Monia, Stanley T. Crooke, Rosanne M. Crooke   +6 more
doaj   +1 more source

Plasminogen Activator Inhibitor‐1 is Internalized by Endothelial Cells via A Pinocytosis‐Like Mechanism and Evades Degradation

The FASEB Journal, Volume 40, Issue 10, 31 May 2026.
Plasminogen activator inhibitor 1 (PAI1) is a secreted protein that also regulates intracellular processes, such as inhibition of endothelial nitric oxide synthase (eNOS). Interaction between Plasminogen Activators (PA) and PAI1 results in a covalent linkage.
Molly McAdow, Gjina Ahmetaj, Rachel Hauschel, Anne Eichmann, William Sessa   +4 more
wiley   +1 more source

Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors

Clinical Case Reports
Key Clinical Message Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment ...
Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino   +5 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

MedComm
Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential.
Jia Kuang, Lei Hao, Meibiao Zhang, Zhao Yang   +3 more
doaj   +1 more source

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives

Vascular Health and Risk Management, 2017
Alberico Luigi Catapano,1,2 Angela Pirillo,1,2 Giuseppe Danilo Norata1,3,4 1Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, 2IRCCS Multimedica Hospital, Sesto San Giovanni, 3Center for the Study of ...
Catapano AL, Pirillo A, Norata GD
doaj  

Therapeutic Strategies for Hypercholesterolemia

healthbook TIMES Das Schweizer Ärztejournal Journal Des Médecins Suisses
A high cholesterol level in the blood is associated with an increased risk of atherosclerosis and its related conditions such as heart attack and stroke.
Georg Noll, André Linka, Thomas Lüscher, Isabella Sudano   +3 more
doaj   +1 more source

Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment. [PDF]

J Am Heart Assoc
Yu L, Xiang B, Ren Y, Li Y, Xie J, Zhou X.   +5 more
europepmc   +1 more source

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

Lipid-lowering drugs and essential hemorrhagic thrombocythemia's risk: A drug-target Mendelian randomization study. [PDF]

Medicine (Baltimore)
Zhang P, Wang H, Lin M, Dai P, Zhong Q, Wang R, Sheng L, He Z, Nan Z.   +8 more
europepmc   +1 more source